Avaliação de métodos na detecção da MIC de vancomicina e mudanças na acurácia relacionada a diferentes valores de MIC by Rossatto, Fernanda Cristina Possamai et al.
Rev. Inst. Med. Trop. Sao Paulo
56(6):469-472, November-December, 2014
doi: 10.1590/S0036-46652014000600002
Sponsorships: CNPq, FAPERGS.
(1) Department of Microbiology, Federal University of Health Science of Porto Alegre, Porto Alegre, RS, Brazil.
(2) Department of Microbiology, Mãe de Deus Hospital, Porto Alegre, RS, Brazil.
Correspondence to: Pedro Alves d’Azevedo, Departamento de Microbiologia, Universidade Federal de Porto Alegre, R. Sarmento Leite 245, 90050-170 Porto Alegre, Rio Grande do Sul, 
Brasil. Tel.: +55 (51) 3303-9000, Fax +55 (51) 3303-8810. E-mail: pedro_dazevedo@yahoo.com.br
EVALUATION OF METHODS IN DETECTING VANCOMYCIN MIC AMONG MRSA ISOLATES AND THE 
CHANGES IN ACCURACY RELATED TO DIFFERENT MIC VALUES
Fernanda Cristina Possamai ROSSATTO(1), Letícia Auler PROENÇA(1), Ana Paula BECKER(1,2),  
Alessandro Conrado de Oliveira SILVEIRA(1), Juliana CAIERÃO(1) & Pedro Alves D’AZEVEDO(1)
SUMMARY
INTRODUCTION: Methicillin-Resistant Staphylococcus aureus (MRSA) presenting reduced susceptibility to vancomycin 
has been associated to therapeutic failure. Some methods used by clinical laboratories may not be sufficiently accurate to detect this 
phenotype, compromising results and the outcome of the patient. OBJECTIVES: To evaluate the performance of methods in the 
detection of vancomycin MIC values among clinical isolates of MRSA. MATERIAL AND METHODS: The Vancomycin Minimal 
Inhibitory Concentration was determined for 75 MRSA isolates from inpatients of Mãe de Deus Hospital, Porto Alegre, Brazil. The 
broth microdilution (BM) was used as the gold-standard technique, as well as the following methods: E-test® strips (BioMérieux), 
M.I.C.E® strips (Oxoid), PROBAC® commercial panel and the automated system MicroScan® (Siemens). Besides, the agar screening 
test was carried out with 3 µg/mL of vancomycin. RESULTS: All isolates presented MIC ≤ 2 µg/mL for BM. E-test® had higher 
concordance (40%) in terms of global agreement with the gold standard, and there was not statistical difference among E-test® and 
broth microdilution results. PROBAC® panels presented MICs, in general, lower than the gold-standard panels (58.66% major errors), 
while M.I.C.E.® MICs were higher (67.99% minor errors). CONCLUSIONS: For the population of MRSA in question, E-test® 
presented the best performance, although with a heterogeneous accuracy, depending on MIC values.
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INTRODUCTION
Methicillin-resistant Staphylococcus aureus (MRSA) is one of the 
most important bacterial pathogens worldwide, especially in healthcare 
associated infections7. As MRSA is almost always multiresistant, 
vancomycin is the therapy of choice. In 2007, the Clinical and Laboratory 
Standards Institute (CLSI) determined the reduction of breakpoints 
for Minimal Inhibitory Concentration (MIC) of vancomycin among 
S. aureus to increase the sensitivity in detecting the non-susceptible 
isolates5. The apparent increase in vancomycin MIC among MRSA, 
observed in the last years, could represent the first step for the occurrence 
of fully resistant isolates. Indeed, the emergence of strains has been 
determined by presenting intermediate resistance (VISA) or hetero-VISA 
(vancomycin-intermediate S. aureus). Besides, increasing proportions 
of MRSA isolates with high MICs have been observed within the 
susceptible range, a phenomenon known as vancomycin MIC creep8,10. 
These isolates with MIC creep have been associated with therapeutic 
failure13,18, as vancomycin may be ineffective against isolates with MICs 
between 1 and 2 µg/mL8.
Several methods with variable sensitivity and specificity are available 
to determine vancomycin MIC. According to CLSI, broth microdilution 
(BM) is considered the gold standard5. However, because it is time-
consuming, a considerable number of clinical laboratories do not use it 
as routine methodology. Other techniques have been widely used, with 
variable sensitivity and specificity, such as automated systems, strips 
with antimicrobial concentration gradient and microdilution commercial 
panels6. The objective of this study was to evaluate the accuracy of 
several methods in the characterization of vancomycin MIC among 
clinical MRSA isolates.
MATERIAL AND METHODS
Bacterial isolates: Seventy-five MRSA from Mãe de Deus hospital, 
a 400-bed general hospital in Porto Alegre, were evaluated in Southern 
Brazil. Methicillin resistance was first characterized by automated system 
(MicroScan Walk Away, Siemens®), MRSA phenotype was confirmed 
by molecular methods (mecA gene), described elsewhere20. Isolates 
were maintained (-20 ºC) in 10% Skim Milk (Difco, Detroit, USA) with 
10% glycerol. 
Determination of Minimal Inhibitory Concentration: Vancomycin 
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MICs were determined by BM6 and by the following techniques, 
according to the manufacturer’s instructions: E-test® strips (BioMérieux, 
Marcy l’Étoile, France), M.I.C.E.® strips (Oxoid, Thermo Fisher 
Scientific, Basingstoke, UK), MicroScan and commercial panels for 
MIC detection (PROBAC®). Besides, the agar dilution screening test was 
performed with 3 µg/mL of vancomycin, as proposed by BURNHAM, 
WEBER & DUNNE1.
 
A vancomycin-susceptible strain (ATCC 25923) 
and a positive control (Enterococcus faecalis carrying vanA gene) were 
used for all methodologies.
Statistical analysis: Descriptive statistics were applied, and data 
were evaluated by ANOVA, followed by the Tukey post hoc test. The 
results were processed using the Statistical Package for Social Sciences 
(SPSS) 17.0. Results statistically significant were considered when p 
< 0.05. 
RESULTS
The 75 MRSA evaluated were susceptible to vancomycin with MICs 
≤ 2 µg/mL (BM): 2 µg/mL (4%), 1 µg/mL (50.66%), 0.5 µg/mL (42.66%), 
and 0.25 µg/mL (2.66%). The MIC50 and MIC90 were both 1 µg/mL. All 
isolates were susceptible to vancomycin for agar dilution screening. The 
MicroScan panel used had four dilution points (16, 8, 4 and 2 µg/mL) 
and all isolates presented MICs ≤ 2 µg/mL. 
The E-test® was statistically similar to BM (p = 0.777). However, 
PROBAC® and M.I.C.E.® were both statistically different compared to 
the gold standard (p < 0.001). 
For the E-test® analysis, two approaches were used: the first one 
used the gross values; for the second approach, CLSI breakpoints for 
BM were used to evaluate the E-test® (i.e. an E-test MIC of 3 was, for 
this approach, considered 4 µg/mL). This data are shown in Table 1.
The agreement among evaluated methods and BM was also evaluated, 
considering each MIC value to observe if the performance of the methods 
depended on the MIC value, as shown in Table 2.
Considerable heterogeneous performance was observed in different 
MIC values. In MRSA isolates with a vancomycin MIC of 0.25 µg/mL, 
the E-test® and M.I.C.E.® presented values at least 1-fold higher than BM 
for all isolates; which was also observed in most isolates with a MIC of 
0.5 µg/mL. However, for a MIC of 1 and 2 µg/mL, higher agreements 
for both strip-based methodologies (Table 2) were observed. For these 
methods, discordant results showed MICs 1-fold higher than BM for 
MIC 1 µg/mL. On the other hand, for MIC 2 µg/mL, all discordant 
results presented MICs lower than the gold standard method. Regarding 
the commercial panel PROBAC®, better performances were observed in 
lower MICs (0.25 and 0.5 µg/mL). For MICs 1 and 2 µg/mL, discordance 
was a major concern (Table 2).
In terms of global agreement with the gold standard, the E-test® had 
higher concordance (40%) and it was the only one statistically similar 
to BM, followed by PROBAC® (36%), which had a higher number of 
major errors (58.66%). Minor errors were mostly observed for M.I.C.E.® 
strips (67.99%).
DISCUSSION
The therapeutic failure related to vancomycin is well established, 
especially regarding to MIC creeps13. Most hospitals report estimated 
vancomycin MICs through automated methods. However, different 
authors show evidence that MIC creeps are not accurately detected 
by automated systems8,9. The failure during vancomycin therapy is 
particularly associated to pharmacokinetic and pharmacodinamic 
characteristics of the drug, which needs a ratio area under the curve/MIC 
higher than 400 to obtain therapeutic success. When isolates present a 
MIC of 2 µg/mL, this ratio is hard to achieve, once serum vancomycin 
concentration should be 15 and 20 µg/mL19.
In this study, the E-test® was, in general, the method with a higher 
agreement with BM, presenting the most homogeneous performance 
in different MIC values. The commercial panel PROBAC® presented 
better performance in lower MIC data regarding these panels, which is 
extremely relevant, considering the absence of previous information on 
Table 1
Distribution of MRSA according to MIC values and methodologies
MIC (µg/mL) Methodology % (n)
Broth microdilution PROBAC® E-test® E-test®*** M.I.C.E.®
0.25 2.66% (2) 18.66% (14) 1.33% (1) 1.33% (1) 1.33% (1)
0.38* NA** NA** 5.33% (4) NA** NA**
0.50 42.66% (32) 68% (51) 14.66% (11) 20% (15) 2.66% (2)
0.75* NA** NA** 25.33% (19) NA** NA**
1.00 50.66% (38) 13.33% (10) 30.66% (23) 56% (42) 38.66% (29)
1.50* NA** NA** 22.66% (17) NA** NA**
2.00 4% (3) 0% (0) 0% (0) 22.66% (17) 57.33% (43)
100% (75) 100% (75) 100% (75) 100% (75) 100% (75)
MRSA: Methicillin-resistant Staphylococcus aureus; MIC: Minimal Inhibitory Concentration; *MICs value observed only on E-test® strip; **NA = not applicable; 
***CLSI breakpoints for BM were used for the evaluation of E-tests results.
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the performance of this method. To the authors’ knowledge, this is the first 
study to evaluate the accuracy of MICs determined by PROBAC® panels. 
On the other hand, M.I.C.E.® had better performance with higher 
MICs. Global agreement of M.I.C.E.® (28%) was considerably lower than 
that observed by CAMPANA et al. (2011) (76.3%). Besides, MUSHTAQ 
et al. (2010) observed elevated rates of agreement between the strips 
(M.I.C.E.® and E-test®), concluding that both are appropriate for clinical 
laboratory use. In this study, the low global agreement of M.I.C.E.® strips 
does not point them as accurate methods.
VAN HAL et al. (2012), in his meta-analysis, showed no statistical 
difference between mortality associated with infections caused by S. 
aureus strains and vancomycin MIC of 1.5 µg/mL and 1 µg/mL. However, 
mortality associated with strains presenting MIC 2 µg/mL and 1.5 µg/
mL was statistically different. Therefore, the interpretation of M.I.C.E.® 
results is compromised, once it does not present the 1.5 µg/mL value of 
MIC. So, the M.I.C.E.® MIC of 2 µg/mL may, in fact, represent 1.5 µg/
mL or 2 µg/mL, which could lead to therapeutic failure. 
According to SWENSON et al. (2009) and RYBAC et al. (2013), 
the E-test® and MicroScan lead to a higher BM of MIC 1-fold. CDC 
recommends that the clinical laboratory should define an algorithm to 
determine which additional tests would be necessary to confirm an S. 
aureus as having reduced susceptibility to vancomycin. This algorithm 
should consider characteristics of patients and resources available 
in the clinical laboratory3. As MIC average of population may affect 
performance of tests, it should be considered when choosing alternative 
methodologies for broth microdilution. 
For the MRSA isolates tested, the E-test® presented the best 
performance. Even though, overestimated MIC, also described by other 
authors, compromises the accuracy of the method. Nevertheless, these 
non-accurate MICs represent minor errors, which have lower impact on 
the treatment of patients, compared to major errors. So, this data support 
the use of the E-test® as a rapid and easy test.
This study has some limitations. First, the reduced number of 
isolates could have compromised the statistical analysis. Second, the 
MRSA population tested presented low MICs; studies with a different 
population of MRSA must be conducted to evaluate the performance of 
methods in strains with higher chances of leading to therapeutic failures 
and determining if differences in performance would also be observed. 
Another point of concern is that MIC values may suffer alterations 
after cryopreservation. EDWARDS et al. (2012) demonstrated that 
MICs from automated systems and the E-test® were significantly 
lower after cryopreservation, if compared with those from the E-test® 
analysis, at the time of isolation, either for vancomycin and daptomycin. 
SCHAUMBURG et al. (2014) also pointed out that the prevalence 
of vancomycin MIC creeps may be underestimated because of the 
cryopreservation effect. Therefore, vancomycin MIC creeps might be 
lost after cryoconservation8,16. This variable was not considered as the 
study population. Further studies must be designed to reinforce previous 
observations.
Monitoring the occurrence of S. aureus with reduced susceptibility to 
vancomycin is a subject. For the population of MRSA tested, the E-test® 
presented the best performance, although with heterogeneous accuracy, 
Table 2
Agreement (%) among methods and BM, according to vancomycin MIC values
Broth microdilution 
MIC (µg/mL) Methodology Agreement % (n) Lower MIC
#
 % (n) 1X higher## MIC % (n) 2X higher### MIC % (n)
0.25
PROBAC® 50.00% (1) 0.00% (0) 50.00% (1) 0.00% (0)
E-test® * 0.00% (0) 0.00% (0) 50.00% (1) 50.00% (1)
M.I.C.E.® 0.00% (0) 0.00% (0) 0.00% (0) 100.00% (2)
0.50
PROBAC® 59.37% (19) 31.25% (10) 9.38% (3) 0.00% (0)
E-test® * 25.00% (8) 0.00% (0) 56.25% (18) 18.75% (6)
M.I.C.E.® 3.12% (1) 3.12% (1) 28.13% (9) 65.63% (21)
1.00
PRΟΒΑC® 18.42% (7) 81.58% (31) 0.00% (0) 0.00% (0)
E-test® * 55.26% (21) 18.42% (7) 26.32% (10) 0.00% (0)
M.I.C.E.® 47.37% (18) 2.63% (1) 50.00% (19) 0.00% (0)
2.00
PROBAC® 0.00% (0) 100.00% (3) 0.00% (0) 0.00% (0)
E-test® * 33.33% (1) 66.67% (2) 0.00% (0) 0.00% (0)
M.I.C.E.® 66.67% (2) 33.33% (1) 0.00% (0) 0.00% (0)
Global agreement
PROBAC® 36.00% (27) 58.66% (44) 5.33% (4) 0.00% (0)
E-test® * 40.00% (30) 12.00% (9) 38.66% (29) 9.33% (7)
M.I.C.E.® 28.00% (21) 4.00% (3) 37.33% (28) 30.66% (23)
*CLSI breakpoints for BM were used for the evaluation of E-tests® results; #MICs were defined as lower than the BM; ## MICs were defined as one-fold dilution higher 
than the BM; ### MICs were defined as two-fold dilution higher than the BM.
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depending on MIC values. Thus, the choice of method to determine 
MIC values must take into consideration costs, conditions of the clinical 
laboratory and the characteristics of the S. aureus populations evaluated. 
RESUMO
Avaliação de métodos na detecção da MIC de vancomicina e 
mudanças na acurácia relacionada a diferentes valores de MIC
INTRODUÇÃO: Staphylococcus aureus resistente à meticilina 
(MRSA) apresentando suscetibilidade reduzida à vancomicina tem 
sido associado à falha terapêutica. Alguns métodos utilizados por 
laboratórios clínicos podem não ser suficientemente precisos para 
detectar este fenótipo, comprometendo os resultados e o desfecho do 
paciente. OBJETIVOS: Avaliar o desempenho de métodos na detecção 
dos valores de MIC de vancomicina entre isolados clínicos de MRSA. 
MATERIAIS E MÉTODOS: Determinamos a Concentração Inibitória 
Mínima de Vancomicina para 75 MRSA isolados de pacientes do Hospital 
Mãe de Deus, Porto Alegre, Brasil. Utilizamos a microdiluição em 
caldo como técnica padrão-ouro e os seguintes métodos: tiras de E-test® 
(BioMérieux), tiras M.I.C.E® (Oxoid), painel comercial da PROBAC® e 
sistema automatizado MicroScan® (Siemens). Além disso, foi realizado o 
teste de triagem em ágar com 3 µg/mL de vancomicina. RESULTADOS: 
Todos os isolados apresentaram MIC ≤ 2 µg/mL. Não houve diferença 
estatística entre os resultados do E-test® e da microdiluição em caldo. O 
painel da PROBAC® apresentou MICs, em geral, menores que o padrão-
ouro (58,66% de erros maiores), enquanto que as MICs pelo M.I.C.E.® 
foram maiores (67,99% de erros menores). CONCLUSÕES: Para nossa 
população de MRSA, E-test® apresentou o melhor desempenho, embora 
com uma acurácia heterogênea, dependendo dos valores da MIC.
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